Comparison of patient background between a real‐world North American cohort and the Göteborg‐2 trial

Abstract

ObjectivesTo analyze the generalizability of the Göteborg‐2 findings to a North American cohort.MethodsWe replicated the Göteborg‐2 inclusion criteria in our Henry Ford Health (HFH) cohort, by identifying all patients 50–60 years old who had a PSA test from 2013 to 2018. The first PSA within the study period was considered PSA at entry, and included in the analysis. Chi‐square test was used to compare categorical variables between the Göteborg‐2 and HFH cohort, with a particular focus on Black men, who were also analyzed separately.ResultsThe HFH patients included in the cohort were 49 456, of which 8562 were Black. In patients within the entire HFH cohort, HFH Black cohort, Göteborg Reference cohort, and Göteborg Experimental cohort, the rate of PSA ≥3 ng/mL was, respectively, 6.8%, 10.2%, 6.8%, and 6.6%. The rate of biopsy performed was, respectively, 1.8%, 4.1%, 5.8%, and 2.5%. PCa was found in, respectively, 1.4%, 3.0%, 2.3%, and 1.5%; Gleason score 3 + 3 in, respectively, 0.5%, 0.8%, 1.2%, and 0.6%; Gleason score > 3 + 3 in, respectively, 0.9%, 2.2%, 1.1%, and 0.9%.ConclusionsOur cohort had a lower biopsy rate and a lower incidence of non‐csPCa diagnosis than both Göteborg cohorts, while still maintaining the same incidence of csPCa. This implies that the benefits of reducing non‐csPCa diagnosis, as observed in the Experimental Göteborg cohort, are not necessarily replicable in U.S. “real‐world practice” patients. Also noteworthy, we had a significantly higher percentage of Black men, who showed more aggressive disease.